SCHEMBL24975356

SCHEMBL24975356

CCN(C(C)=O)c1ccc(-c2ccc(C(=O)NCc3cccnc3)cn2)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HPGDS O60760 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ TSHR P16473 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HTT P42858 2/20 0.47
▸ MAPT P10636 1/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ TRPV1 Q8NER1 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ PSMD14 O00487 1/20 0.44
▸ STAMBP O95630 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29801250 1.00 LMNA (0.48) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL24975550 0.91 POLB (0.46) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL29801266 0.91 POLB (0.46) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL29801142 0.90 NAMPT (0.49) LMNAMAPK1HPGDSTSHRALDH1A1
SCHEMBL24975321 0.90 NAMPT (0.49) LMNAMAPK1HPGDSTSHRALDH1A1
SCHEMBL24975189 0.90 LMNA (0.45) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL29801154 0.90 LMNA (0.45) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL24975124 0.89 HPGDS (0.49) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL29801092 0.89 HPGDS (0.49) LMNAMAPK1HPGDSRECQLTSHR
SCHEMBL24975147 0.89 NAMPT (0.46) LMNAMAPK1HPGDSRECQLTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 — — US disclosed
CN-114929672-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, KIT, GLI1 LMNA 2667/4885MAPK1 3430/4885HPGDS 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback